All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): UniCAR-T-PSMA
Therapeutic Area: Oncology Product Name: UniCAR-T-PSMA
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Details:
GEMoaB has apheresed the first patient in a Phase IA study with UniCAR-T-PSMA, the lead solid tumor product candidate from its proprietary UniCAR cellular immunotherapy platform.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AFM13,Pembrolizumab
Therapeutic Area: Oncology Product Name: AFM13
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co. Inc.
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Details:
The results demonstrate promising signs of efficacy including an objective response rate of 88% at the highest treatment dose of AFM13 with KEYTRUDA, as well as a complete CR of 46%. As a monotherapy, KEYTRUDA demonstrated an ORR of 69% and a CR of 22.4% in the KEYNOTE-087.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IMA101
Therapeutic Area: Oncology Product Name: IMA101
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
ACTolog® demonstrates feasibility of a multi-target multi-T cell product approach. The target positivity rate of 90% demonstrated that such a multi-target approach leads to minimal patient attrition during screening due to lack of target expression.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AFM13-NK cells,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: AFM13-NK cells
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
AFM13-preloaded cNK cells from healthy donors exhibited superior responses versus those from Hodgkin lymphoma patients suggesting that the source of NK cells impacts tumor cell killing.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AFM13-NK cells,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: AFM13-NK cells
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
Details:
First in human study to combine an NK cell product with an antibody whose primary mechanism is designed to specifically bind and activate NK cells and tumors cells in a bispecific fashion.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BI 905711
Therapeutic Area: Oncology Product Name: BI 905711
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2020
Details:
The first-in-class BI 905711 antibody is designed to recognize both the pro-apoptotic TNF-related apoptosis-inducing ligand receptor 2 and the tumor cell anchor CDH17 to activate apoptosis pathway in co-expressing tumor cells found mostly in the GI tract.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IMA202
Therapeutic Area: Oncology Product Name: IMA202
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2020
Details:
First patient in the IMA202-101 trial in Europe following the Clinical Trial Application (CTA, the equivalent of an IND approval by FDA) approval by Paul-Ehrlich-Institute (PEI), the regulatory body for cell and gene therapies in Germany.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tinostamustine
Therapeutic Area: Oncology Product Name: EDO-S101
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2020
Details:
Tinostamustine is in early phase clinical trials (Phase I) to investigate its use as a potential future treatment option in this area of significant unmet patient need.Tinostamustine is the only medicinal product with an orphan drug designation for T-PLL in the EU.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BNT111
Therapeutic Area: Oncology Product Name: BNT111
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2020
Details:
Safety assessment was performed in 89 advanced melanoma patients treated with intravenously delivered repeated doses of mRNA-based cancer vaccine BNT111 ranging from 7.2µg to 400µg. Overall, BNT111 treatment was well tolerated with no dose limiting toxicity.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MDG1021
Therapeutic Area: Oncology Product Name: MDG1021
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2020
Details:
The Phase I study of MDG1021 will be initiated at the Leiden University Medical Center (LUMC), the Netherlands, and will enroll patients suffering from relapsed or persistent blood cancers after allogeneic (non-self) hematopoietic stem cell transplantation
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
